InterVenn Biosciences vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
InterVenn Biosciences pioneered clinical glycoproteomics with AI-powered liquid biopsy diagnostics for cancer; raised $251M total, received AMA PLA code for non-invasive ovarian cancer test in July 2025.
About
InterVenn Biosciences is a clinical-stage diagnostics company that has pioneered the field of glycoproteomics — the study of proteins modified with sugar molecules (glycans) — combined with artificial intelligence to develop next-generation liquid biopsy tests for cancer detection and treatment monitoring. The company's VOCAL test provides a non-invasive diagnostic for ovarian cancer using a blood draw, and its GlycoKnowPR platform delivers glycoproteomic immunotherapy response assays to help oncologists predict how patients will respond to treatment before administering therapy.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.